Tolerance promoting cells were derived from infused donor bone marrow cell (DBMC) in dogs treated with fractionated lymphoid irradiation (FLI) and FK506 (FK)

我们已经开发了一个安全的区域，因为它可以生产化学和容忍与历史兼容的胡子之间的肾脏信号。基本地区包括前操作FLI、DBMS-肾脏移植（KGT）和FK后操作IM。方法：狗是根据MLR的基本选择的（S.I.=）10），性别错配的，不相关的对和匹配等级由PCR-SSCP确认。他们在3天内处理FLI （150 rad/天），PHA-无反应的DBMS-输液（2 x10 D17 D1/kg）和FK （0.08 mg/kg/天）。用于监测、MLR阻塞试验的性能;反应器细胞（预先操作冻结的储存细胞）反对（D）或固定的第三方细胞（T）作为刺激器细胞准备好和混合细胞正在跟随; R外围淋巴细胞、R淋巴节点细胞和R BMCs;化学分析;淋巴细胞毒性试验;以及来自肾脏（D）和（T）的皮肤分析。结果：他们分为5个群体，如以下; A组）非治疗（n=9）; B）FK，（n=6）; C）FLI，DBMC， ... More （n=3）; D）FLI， FK（n=8）; E）FLI， DBMC， and FK（n=l3）。In group A、B、C、MSD;11、5、7.3 days。D组），在90天内拒绝了7/8的KGS（MSD; 53.2天）。在118天内拒绝SGs（D）和（T）的延长的情况下1公斤。E组） （MSD; 178.8 days）、Rs with persistent chimerism（5/8）、surManagement ed>70 days、one of which had complete acceptance or SGs only from kidney （D）'s。此外，两三个人在相同的性犯罪中存活>200天，只接受肾脏（D）s的SGs。在137天内，3/8的时间内，SGs从（D）和（T）中被拒绝。在E组中有2个长期存活者的染色体），R的外围淋巴细胞、淋巴细胞和BMCs被重复观察到MLR-Blocking研究。在对比中，在（R ）中，任何淋巴细胞都被排斥在化学物质消失的情况下，被观察到的（D）特定淋巴细胞毒性抗体的非抑制。结论性;与FLI、DBMS-灌注和Fk的联合治疗对KGS的延长有效。移植推广因子是从化学骨毛中衍生出来的，特别是阻塞了R反-（D）活动。Less（低）

We have developed safe regimen that can produce chimerism and tolerance to kidney allografts between histoincompatible beagles. The basic regimen included preoperative FLI, DBMC-infusion at kidney grafting (KGT) and postoperative IM of FK. Methods; Dogs were selected on the basis of MLR (S.I.=10), sex-mismatched, unrelated pairs and matching grade was confirmed by PCR-SSCP. They were treated with FLI (150rad/day) for 3 days, PHA-nonresponding DBMC-infusion(2x10ィイD17ィエD1/kg) and FK (0.08mg/kg/d for 90 days). As for monitoring, MLR-blocking test was performed; Responder cells(preoperatively frozen stored cells) against (D) or fixed third-party(T) cells as stimulator cells were prepared, and cocultured cells were as follows; R peripheral lymphocytes, R lymphnode cells, and R BMCs; chimerism analysis by karyotyping; lymphocytotoxicity test; and skingrafting(SGT) from kidney (D) and (T). Results; They were divided into 5 groups, as follows; group A) non-treated(n=9); B)FK,(n=6); C)FLI,DBMC, … More (n=3); D)FLI, FK(n=8); E)FLI, DBMC, and FK(n=l3). In group A), B), C), MSD;11, 5, 7.3 days. In group D), all KGs in 7/8 were rejected within 90 days(MSD; 53.2 days). One KG rejected on 118th days without prolongation of SGs from both (D) and (T). In group E) (MSD; 178.8 days), Rs with persistent chimerism(5/8), survived >70 days, one of which had complete acceptance or SGs only from kidney (D)'s. And also, two of three with same sex-comination survived >200 days with acceptance of SGs only from kidney (D)s. Rs with temporary chimerism in 3/8 were rejected by 137 days without prolongation of SGs from both (D) and (T). In 2 long survivors with chimerism in group E), specific suppression by repopulated R's peripheral lymphocyte, lymphnode cells and BMCs was observed in MLR-blocking study. On the contrary, in (R )s which were rejected with disappearance of chimerism, nonsuppression by any lymphoid cells observed with elevation of (D) specific lymphocytotoxic antibody. Conclusion; Combined treatment with FLI, DBMC-infusion, and Fk was effective in prolongation of KGs. Graft promoting factors derived from chimerric bone marrow specifically blocked R anti-(D) activity. Less